CA2291608C - Recepteurs du facteur neurotrope - Google Patents

Recepteurs du facteur neurotrope Download PDF

Info

Publication number
CA2291608C
CA2291608C CA002291608A CA2291608A CA2291608C CA 2291608 C CA2291608 C CA 2291608C CA 002291608 A CA002291608 A CA 002291608A CA 2291608 A CA2291608 A CA 2291608A CA 2291608 C CA2291608 C CA 2291608C
Authority
CA
Canada
Prior art keywords
gdnfr
amino acid
gdnf
acid sequence
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA002291608A
Other languages
English (en)
Other versions
CA2291608A1 (fr
Inventor
Gary M. Fox
Shuqian Jing
Duanzhi Wen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/866,354 external-priority patent/US7138251B1/en
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CA2291608A1 publication Critical patent/CA2291608A1/fr
Application granted granted Critical
Publication of CA2291608C publication Critical patent/CA2291608C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention porte sur le facteur GDNF, puissante neurotrophine présentant un large spectre d'activités biologiques influant sur de nombreux types de cellules des systèmes nerveux central et périphérique. Elle consiste à cloner et caractériser les récepteurs du GDNF et décrit es séquences d'acides nucléiques et d'acides aminés de produits protéiques du récepteur du GDNF. Un domaine hydrophobe présentant les caractéristiques d'un peptide signal se trouve à l'extrémité N-terminale tandis qu'un deuxième domaine hydrophobe se trouvant à l'extrémité C-terminale intervient dans la fixation du récepteur sur la membrane cellulaire. L'absence de domaine transmembranaire et de zone cytoplasmique indique que le récepteur du GDNF nécessite une ou plusieurs molécules accessoires pour pouvoir intervenir sur la signalisation transmembranaire. L'ARNm du récepteur du GDNF est largement distribué à la fois dans le système nerveux et dans les tissus non nerveux ce qui est en accord avec la distribution similaire trouvée pour le GDNF.
CA002291608A 1997-05-30 1998-04-27 Recepteurs du facteur neurotrope Expired - Lifetime CA2291608C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/866,354 US7138251B1 (en) 1996-04-22 1997-05-30 Polynucleotides encoding a neurotrophic factor receptor
US08/866,354 1997-05-30
PCT/US1998/008486 WO1998054213A2 (fr) 1997-05-30 1998-04-27 Recepteurs du facteur neurotrope

Publications (2)

Publication Number Publication Date
CA2291608A1 CA2291608A1 (fr) 1998-12-03
CA2291608C true CA2291608C (fr) 2004-04-13

Family

ID=25347430

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002291608A Expired - Lifetime CA2291608C (fr) 1997-05-30 1998-04-27 Recepteurs du facteur neurotrope

Country Status (6)

Country Link
EP (1) EP0983354A2 (fr)
JP (1) JP2002505576A (fr)
AU (1) AU7165998A (fr)
CA (1) CA2291608C (fr)
WO (1) WO1998054213A2 (fr)
ZA (1) ZA984404B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6696259B1 (en) 1995-11-13 2004-02-24 Licentia Ltd. Assays using glial cell line-derived neurotrophic factor receptors
US6677135B1 (en) 1996-05-08 2004-01-13 Biogen, Inc. Ret ligand (RetL) for stimulating neutral and renal growth
KR20010012826A (ko) * 1997-05-22 2001-02-26 세파론, 인코포레이티드 신경교 세포주-유래 향신경성 인자 수용체
WO1999049039A2 (fr) * 1998-03-23 1999-09-30 Genentech, Inc. LE GFRα3 ET SES UTILISATIONS
US7026138B1 (en) 1998-03-23 2006-04-11 Genentech, Inc. Polynucleotides encoding GFRα3
DE19816186A1 (de) * 1998-04-14 1999-10-21 Univ Muenchen L Maximilians GDNF-kodierende DNA, Teile davon und GDNF-Varianten
JP6692293B2 (ja) * 2013-07-22 2020-05-13 アーマジェン・インコーポレイテッドＡｒｍａｇｅｎ， Ｉｎｃ． Ｃｎｓにおける酵素活性を増大するための方法および組成物
WO2018089702A1 (fr) 2016-11-10 2018-05-17 Keros Therapeutics, Inc. Polypeptides de fusion gdnf et leurs procédés d'utilisation
AU2020346062A1 (en) * 2019-09-13 2022-03-24 Rutgers, The State University Of New Jersey AAV-compatible laminin-linker polymerization proteins

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4006054A1 (de) * 1990-02-26 1991-08-29 Boehringer Mannheim Gmbh Verfahren zur immunologischen bestimmung von liganden
SG48813A1 (en) * 1993-08-12 1998-05-18 Cytotherapeutics Inc Improved composition and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules
US6455277B1 (en) * 1996-04-22 2002-09-24 Amgen Inc. Polynucleotides encoding human glial cell line-derived neurotrophic factor receptor polypeptides
CN1163509C (zh) * 1996-05-08 2004-08-25 拜奥根有限公司 刺激神经和肾生长的RET配体(RetL)
EP0846764A3 (fr) * 1996-11-27 1998-09-30 Smithkline Beecham Plc Famille de facteurs alpha neurotrophiques des cellules gliales
AU730430B2 (en) * 1997-02-18 2001-03-08 Genentech Inc. Neurturin receptor

Also Published As

Publication number Publication date
EP0983354A2 (fr) 2000-03-08
CA2291608A1 (fr) 1998-12-03
WO1998054213A2 (fr) 1998-12-03
ZA984404B (en) 1998-12-01
JP2002505576A (ja) 2002-02-19
AU7165998A (en) 1998-12-30
WO1998054213A3 (fr) 1999-01-07

Similar Documents

Publication Publication Date Title
CA2250704C (fr) Recepteur de gdnf
JP4909843B2 (ja) 截形グリア細胞系由来神経栄養因子
AU1352497A (en) Novel tyrosine kinase receptors and ligands
US6413740B1 (en) Tyrosine kinase receptors and ligands
WO2000034475A9 (fr) Facteur de croissance neurotrophique issu des cellules gliales (grnf4), un facteur neurotrophique
CA2291608C (fr) Recepteurs du facteur neurotrope
US7138251B1 (en) Polynucleotides encoding a neurotrophic factor receptor
KR100399377B1 (ko) Ｇｄｎｆ 단백질의 분석방법 및 검정 기구
TW509696B (en) Glial cell line-derived neurotrophic factor receptor

Legal Events

Date Code Title Description
EEER Examination request